Enroll in Psychedelics and Medicine on Coursera: www.coursera.org/learn/psyche...

Learn more about our course here: www.hopkinsmedicine.org/news/article...

Dr. Boris Heifets @theborislab.bsky.social closed the conference by urging stronger cross-species feedback. Back-translating human drug effects exposes unexpected mechanisms, refines animal models, and shows why natural variability and larger studies are essential.

Dr. Torben Ott @torbenott.bsky.social demonstrated rodent behavioral and neural models of hallucination-like percepts, emphasizing computational characterization as a powerful way to align measures across species

Dr. Katharina Schmack @kathaschmack.bsky.social opened the afternoon session with her team’s rodent model of hallucination-like percepts, a tool advancing our understanding of hallucinogenesis and pointing toward more targeted antipsychotics.

Dr. Bita Moghaddam @bita137.bsky.social argued that clinically relevant cognitive processes can be modeled in animals and urged human and animal psychedelic researchers to align constructs, measures, and tasks using cognitive neuroscience tools.

Dr. Pierre Blier traced his decades of moving between human and animal studies to uncover ketamine’s antidepressant mechanisms. His cross-species work helped reveal AMPA throughput as key, paving the way for trials targeting this pathway.

Dr. Mark Geyer kicked off our conference, highlighting the two-way street of translational science: developing non-verbal human measures that parallel animal studies.

Read the full review published in the Schizophrenia Bulletin academic.oup.com/schizophreni...